Barrow Robert, CEO, reported an open-market or private sale at Definium Therapeutics, Inc. involving 19023.000000 shares for an estimated $721732.62. Reported holdings after the transaction were 1494640.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
The common shares represent the first tranche of performance share units granted effective February 3, 2026. Each performance share unit represented a contingent right to receive one common share bas…
Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.
Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections u…
The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to p…
0 other filings
0 recent txs